TD Cowen raised the firm’s price target on Cardinal Health to $116 from $109 and keeps a Buy rating on the shares. The firm said they see new contracts signed, expansions, and biosimilar sourcing joint venture Averon driving solid growth in FY25 and FY26.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- CAH Earnings: Cardinal Rises on Raised Outlook & Robust Q4 Results
- Options Volatility and Implied Earnings Moves Today, August 14, 2024
- Cardinal Health Executives to Discuss Annual Financial Results
- Cardinal Health raises FY25 EPS view to $7.55-$7.70 from at least $7.50
- Cardinal Health Reports Fourth Quarter and Fiscal Year 2024 Results and Raises Fiscal Year 2025 Guidance